How should I taper and discontinue Rexulti (brexpiprazole) 2 mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Tapering Rexulti (Brexpiprazole) 2mg

The FDA label does not provide specific tapering instructions for discontinuing Rexulti, but based on APA guidelines for antipsychotics in dementia and general principles of antipsychotic discontinuation, you should taper gradually rather than stop abruptly to minimize withdrawal symptoms and monitor for symptom recurrence.

Clinical Context for Discontinuation

Before initiating a taper, you must determine whether discontinuation is appropriate:

  • If no response after 4 weeks at adequate dose: Taper and withdraw the medication 1
  • If clinically significant side effects occur: Review risks/benefits and consider tapering 1
  • If positive response achieved: Periodically reassess continued need 2

Recommended Tapering Approach

Standard Taper Schedule

Since the FDA label shows titration UP occurs over 1-2 weeks 2, reverse this schedule when tapering down:

  • Week 1: Reduce from 2 mg to 1 mg daily
  • Week 2: Reduce from 1 mg to 0.5 mg daily
  • Week 3: Reduce from 0.5 mg to 0.25 mg daily
  • Week 4: Discontinue

Slower Taper for High-Risk Patients

Consider extending the taper over 4-8 weeks or longer if the patient has:

  • Been on Rexulti for >6 months
  • History of withdrawal symptoms from other medications
  • Severe baseline symptoms
  • Previous relapse with rapid discontinuation

For these patients, hold each dose reduction for 2 weeks before proceeding to the next step.

Monitoring During Taper

Assess every 1-2 weeks during tapering for:

  • Withdrawal symptoms: Akathisia (most common with brexpiprazole 3), insomnia, anxiety, nausea, headache
  • Symptom recurrence: Use quantitative measures like CMAI for agitation or CGI-S 1
  • Distinguish withdrawal from relapse: Withdrawal typically occurs within days of dose reduction and improves with time; relapse develops more gradually over weeks

Key Pitfalls to Avoid

  • Do not stop abruptly: This increases risk of withdrawal symptoms and symptom rebound
  • Do not confuse akathisia with anxiety or agitation: Akathisia was the most common adverse event leading to discontinuation in real-world use 3 and can emerge during tapering
  • Do not automatically restart at full dose if symptoms emerge: Consider pausing the taper at current dose for 1-2 weeks, or reducing by smaller increments

Special Considerations

If the patient is on concomitant CYP3A4 inducers that were discontinued, the FDA label specifically states to "reduce the REXULTI dosage to the original level over 1 to 2 weeks" 2, supporting a gradual taper approach.

For patients with dementia and agitation, involve the patient's surrogate decision maker and family in the tapering decision, discussing observed benefits, side effects, and risks of continued exposure 1.

If withdrawal symptoms occur during taper: Slow the taper, return to the previous dose temporarily, or use smaller dose decrements (the 0.25 mg tablet strength allows for very gradual reductions 2).

References

Related Questions

For a patient who recently started rexulti (brexpiprazole) and is aggressively hitting staff after receiving oral haloperidol, what emergency medication should be administered?
Is it safe to take brexpiprazole (Rexulti) 2 mg together with bupropion XL (Wellbutrin) 150 mg?
What are the approved clinical uses of brexpiprazole?
Can I start brexpiprazole (Braylar) 1.5 mg while tapering lithium 600 mg daily?
What is the recommended starting dose of Rexulti (brexpiprazole) and its titration schedule?
What are the recommended guidelines for managing a patient who has bowel movements every other day and no alarm symptoms?
What is the recommended acute management for a patient presenting with an acute ischemic stroke?
Can dexamethasone be administered intramuscularly for breakthrough vomiting after first- and second-line antiemetic failure?
In a formulation with a high concentration of benzocaine (benzo) or alcohol, which route—intramuscular (IM) or subcutaneous (SC)—is more irritating?
What dexamethasone dosing regimen is appropriate for a 23‑year‑old female weighing 140 lb who is experiencing persistent vomiting?
What are the possible causes of lower right leg muscle twitches and cramps in a 59-year-old man with abnormal electromyography and nerve conduction studies?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.